Drug Profile
EC NGF
Alternative Names: EC-NGF; ECB-AD; ECT-AD; ECT-NGF; Nerve growth factor secreting encapsulated cell therapy; NsG0202Latest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator NsGene USA
- Developer Gloriana Therapeutics
- Class Antidementias; Cell therapies; Gene therapies; Nerve growth factors; Neuroprotectants
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for phase-I development in Alzheimer's-disease in Sweden (Intracerebral, Implant)
- 05 Dec 2019 NsGene USA is now called Gloriana Therapeutics
- 05 Nov 2019 EC-NGF is still in phase-I development in Alzheimer's-disease in Sweden (Intracerebral, Implant) (Gloriana therapeutics website November 2019)